Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Pediatric Blood & Cancer
|
January 22, 2013
The impact of the written request process on drug development in childhood cancer
Kristen M Snyder, Gregory Reaman, Debbie Avant, et al.
Journal of Clinical Pharmacology
|
April 25, 2015
Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling
Jian Wang, Andrea N Edginton, Debbie Avant, et al.
Pharmacoepidemiology and Drug Safety
|
December 22, 2015
Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success
Scott K Winiecki, M Isabel Tejero-Taldo, Debbie Avant, et al.
JAMA Pediatrics
|
November 20, 2018
Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration
Kanecia O Zimmerman, P Brian Smith, Ann W McMahon, et al.
Pediatrics
|
July 16, 2014
Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy
Gerold T Wharton, M Dianne Murphy, Debbie Avant, et al.
Therapeutic Innovation & Regulatory Science
|
August 15, 2017
Neonatal Safety Information Reported to the FDA During Drug Development Studies
Debbie Avant, Gerri Baer, Jason Moore, et al.
JAMA
|
September 14, 2006
Peer-reviewed publication of clinical trials completed for pediatric exclusivity
Daniel K Benjamin, Philip Brian Smith, M Dianne Murphy, et al.
JAMA Pediatrics
|
December 11, 2013
Drug labeling and exposure in neonates
Matthew M Laughon, Debbie Avant, Nidhi Tripathi, et al.
Pediatric Nephrology (Berlin, Germany)
|
August 6, 2017
Effect of renal function on antihypertensive drug safety and efficacy in children
Kevin M Watt, Debbie Avant, Jennifer Sherwin, et al.
Archives of Pediatrics & Adolescent Medicine
|
December 10, 2009
Safety and transparency of pediatric drug trials
Daniel K Benjamin, P Brian Smith, M Jessica M Sun, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Pediatric Blood & Cancer
|
January 22, 2013
The impact of the written request process on drug development in childhood cancer
Kristen M Snyder, Gregory Reaman, Debbie Avant, et al.
Journal of Clinical Pharmacology
|
April 25, 2015
Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling
Jian Wang, Andrea N Edginton, Debbie Avant, et al.
Pharmacoepidemiology and Drug Safety
|
December 22, 2015
Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success
Scott K Winiecki, M Isabel Tejero-Taldo, Debbie Avant, et al.
JAMA Pediatrics
|
November 20, 2018
Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration
Kanecia O Zimmerman, P Brian Smith, Ann W McMahon, et al.
Pediatrics
|
July 16, 2014
Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy
Gerold T Wharton, M Dianne Murphy, Debbie Avant, et al.
Therapeutic Innovation & Regulatory Science
|
August 15, 2017
Neonatal Safety Information Reported to the FDA During Drug Development Studies
Debbie Avant, Gerri Baer, Jason Moore, et al.
JAMA
|
September 14, 2006
Peer-reviewed publication of clinical trials completed for pediatric exclusivity
Daniel K Benjamin, Philip Brian Smith, M Dianne Murphy, et al.
JAMA Pediatrics
|
December 11, 2013
Drug labeling and exposure in neonates
Matthew M Laughon, Debbie Avant, Nidhi Tripathi, et al.
Pediatric Nephrology (Berlin, Germany)
|
August 6, 2017
Effect of renal function on antihypertensive drug safety and efficacy in children
Kevin M Watt, Debbie Avant, Jennifer Sherwin, et al.
Archives of Pediatrics & Adolescent Medicine
|
December 10, 2009
Safety and transparency of pediatric drug trials
Daniel K Benjamin, P Brian Smith, M Jessica M Sun, et al.
Page
of 2